Three startups aim to raise $400 mln as US biotech IPOs gain traction
Adds analyst comments in paragraphs 4-5
By Niket Nishant
Oct 7 (Reuters) -Three healthcare startups are looking to raise up to $400 million in their U.S. initial public offerings, underscoring the sector's strong rebound in 2024 after a two-year slump.
September was the busiest month for healthcare IPOs this year, Dealogic data showed. Strong debuts by companies such as BioAge Labs BIOA.O and Bicara Therapeutics BCAX.O have also encouraged listings among other IPO candidates.
Meanwhile, startups are looking to take advantage of the early stages of a potential interest rate-cutting cycle by the Federal Reserve, even though the uncertainty around the U.S. presidential election next month is likely to keep a lid on funding activity toward the end of the year.
"(Biotechs) may want to capture the current market momentum rather than waiting for elections or economic indicators," said Zara Muradali, national managing principal of Grant Thornton's life sciences industry practice.
"As private equity and venture capital firms seek exits for their investments, there may be pressure on biotech companies to list sooner rather than later."
Upstream Bio, developing treatments for some respiratory disorders, is aiming for up to $212.5 million. Kaiser Permanente-backed CAMP4 Therapeutics, working on therapies for a range of genetic diseases, is seeking $80 million.
CeriBell is targeting up to $107.2 million. The company makes monitors to detect neurological conditions and is backed by TPG's The Rise Fund.
"A company with a product that's in a clinical trial is mature and it likely took a significant round of private capital in order to get there. Those will try to tap the market," said Ross Carmel, partner at securities law firm Sichenzia Ross Ference Carmel.
While the IPO market has recovered from the lows of last year, investors continue to support companies with an established business model and a clearer path to profitability.
Upstream is evaluating its chief product in a mid-stage trial, while CAMP4's therapy is being assessed in an early-stage trial. Both have not generated any revenue from sales. CeriBell already fetches revenue.
All of them will list on the Nasdaq, with Upstream trading under the symbol "UPB", CAMP4 under "CAMP" and CeriBell using "CBLL".
Biotech IPOs blossom in the fall US IPO market https://reut.rs/4dFPx5A
Reporting by Niket Nishant and Arasu Kannagi Basil in Bengaluru; Editing by Leroy Leo and Shilpi Majumdar
免责声明: XM Group仅提供在线交易平台的执行服务和访问权限，并允许个人查看和/或使用网站或网站所提供的内容，但无意进行任何更改或扩展，也不会更改或扩展其服务和访问权限。所有访问和使用权限，将受下列条款与条例约束：(i) 条款与条例；(ii) 风险提示；以及(iii) 完整免责声明。请注意，网站所提供的所有讯息，仅限一般资讯用途。此外，XM所有在线交易平台的内容并不构成，也不能被用于任何未经授权的金融市场交易邀约和/或邀请。金融市场交易对于您的投资资本含有重大风险。
所有在线交易平台所发布的资料，仅适用于教育/资讯类用途，不包含也不应被视为用于金融、投资税或交易相关咨询和建议，或是交易价格纪录，或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。
本网站上由XM和第三方供应商所提供的所有内容，包括意见、新闻、研究、分析、价格、其他资讯和第三方网站链接，皆保持不变，并作为一般市场评论所提供，而非投资性建议。所有在线交易平台所发布的资料，仅适用于教育/资讯类用途，不包含也不应被视为适用于金融、投资税或交易相关咨询和建议，或是交易价格纪录，或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。请确保您已阅读并完全理解，XM非独立投资研究提示和风险提示相关资讯，更多详情请点击 这里。
